Drug major GlaxoSmithKline Pharmaceuticals Ltd
after receiving approval from the regulatory Drug Controller General of India
expects to launch Revolade, a drug for low platelet counts and Votrient, for
metastatic renal cell carcinoma, in the first quarter of the forthcoming year.
The company's growth in the third quarter ended September 2010 has been in line with expectations with patented drugs, vaccines and mass products contributing to the robust growth. Vaccines grew 34 per cent in the quarter under review that global supply issues had "substantially" been addressed. Vaccines account for about 10 per cent of sales. And drugs under price control accounted for 25 per cent of sales.
Between the company's new product launches and in-licensed products, growth in the months ahead is also expected to be along projected lines of 15 per cent.
The company's growth in the third quarter ended September 2010 has been in line with expectations with patented drugs, vaccines and mass products contributing to the robust growth. Vaccines grew 34 per cent in the quarter under review that global supply issues had "substantially" been addressed. Vaccines account for about 10 per cent of sales. And drugs under price control accounted for 25 per cent of sales.
Between the company's new product launches and in-licensed products, growth in the months ahead is also expected to be along projected lines of 15 per cent.
No comments:
Post a Comment